Do analysts rate FLNA or LIAN?

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 311.96%. Given Cassava Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, FLNA or LIAN?

Cassava Sciences is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is FLNA or LIAN more profitable?

LianBio's return on equity of -33.17% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% LianBio N/A -33.17% -30.19%

Do analysts recommend CTOR or LIAN?

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 751.06%. Given Citius Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Citius Oncology is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, CTOR or LIAN?

Citius Oncology is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is CTOR or LIAN more profitable?

LianBio's return on equity of -33.17% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% LianBio N/A -33.17% -30.19%

Do analysts recommend EXOZ or LIAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, EXOZ or LIAN?

eXoZymes has higher revenue and earnings than LianBio. eXoZymes is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 934.62 -$9.16M -$1.14 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is EXOZ or LIAN more profitable?

LianBio's return on equity of -33.17% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% LianBio N/A -33.17% -30.19%

Do analysts rate LIAN or TCRX?

TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 525.65%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer CING or LIAN?

Cingulate presently has a consensus price target of $27.33, indicating a potential upside of 460.80%. Given Cingulate's stronger consensus rating and higher probable upside, research analysts clearly believe Cingulate is more favorable than LianBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, CING or LIAN?

Cingulate is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A LianBio N/A N/A -$110.29M -$0.81 N/A

Is CING or LIAN more profitable?

LianBio's return on equity of -33.17% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% LianBio N/A -33.17% -30.19%

LianBio (LIAN) Competitors

$0.16 +0.05 (+44.58%)

As of 06/12/2026

Compare

LIAN vs. FLNA, CTOR, EXOZ, TCRX, and CING

Should you buy LianBio stock or one of its competitors? MarketBeat compares LianBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LianBio include Cassava Sciences (FLNA), Citius Oncology (CTOR), eXoZymes (EXOZ), TScan Therapeutics (TCRX), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry.

How does LianBio compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 311.96%. Given Cassava Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cassava Sciences has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

LianBio's return on equity of -33.17% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
LianBio	N/A	-33.17%	-30.19%

Cassava Sciences is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

In the previous week, Cassava Sciences had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Cassava Sciences and 0 mentions for LianBio. Cassava Sciences' average media sentiment score of 0.93 beat LianBio's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
LianBio	Neutral

Summary

LianBio beats Cassava Sciences on 7 of the 13 factors compared between the two stocks.

How does LianBio compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Citius Oncology is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LianBio's return on equity of -33.17% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
LianBio	N/A	-33.17%	-30.19%

Citius Oncology has a beta of 3.42, suggesting that its stock price is 242% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 751.06%. Given Citius Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Citius Oncology is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Citius Oncology had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Citius Oncology and 0 mentions for LianBio. Citius Oncology's average media sentiment score of 1.89 beat LianBio's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Very Positive
LianBio	Neutral

Summary

Citius Oncology beats LianBio on 9 of the 13 factors compared between the two stocks.

How does LianBio compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

eXoZymes has a beta of 2.66, indicating that its stock price is 166% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

74.8% of LianBio shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 7.6% of LianBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

eXoZymes has higher revenue and earnings than LianBio. eXoZymes is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	934.62	-$9.16M	-$1.14	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

LianBio's return on equity of -33.17% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
LianBio	N/A	-33.17%	-30.19%

In the previous week, eXoZymes had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for LianBio. eXoZymes' average media sentiment score of 0.98 beat LianBio's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
LianBio	Neutral

Summary

eXoZymes beats LianBio on 7 of the 12 factors compared between the two stocks.

How does LianBio compare to TScan Therapeutics?

LianBio (NASDAQ:LIAN) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

LianBio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. LianBio's return on equity of -33.17% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

74.8% of LianBio shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TScan Therapeutics had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for TScan Therapeutics and 0 mentions for LianBio. TScan Therapeutics' average media sentiment score of 1.87 beat LianBio's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
TScan Therapeutics	Very Positive

TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 525.65%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LianBio has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
TScan Therapeutics	$9.14M	6.86	-$129.77M	-$0.96	N/A

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

TScan Therapeutics beats LianBio on 8 of the 15 factors compared between the two stocks.

How does LianBio compare to Cingulate?

Cingulate (NASDAQ:CING) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

LianBio's return on equity of -33.17% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
LianBio	N/A	-33.17%	-30.19%

Cingulate presently has a consensus price target of $27.33, indicating a potential upside of 460.80%. Given Cingulate's stronger consensus rating and higher probable upside, research analysts clearly believe Cingulate is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

41.3% of Cingulate shares are held by institutional investors. Comparatively, 74.8% of LianBio shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cingulate has a beta of -0.85, meaning that its stock price is 185% less volatile than the broader market. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

In the previous week, Cingulate had 13 more articles in the media than LianBio. MarketBeat recorded 13 mentions for Cingulate and 0 mentions for LianBio. Cingulate's average media sentiment score of 0.93 beat LianBio's score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
LianBio	Neutral

Cingulate is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Summary

LianBio beats Cingulate on 7 of the 13 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIAN vs. The Competition

Export

Metric	LianBio	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.28M	$457.48M	$6.50B	$12.32B
Dividend Yield	N/A	3.88%	2.67%	5.66%
P/E Ratio	-0.20	3.17	24.00	24.65
Price / Sales	N/A	6,569.65	543.88	171.03
Price / Cash	N/A	13.13	27.48	37.92
Price / Book	0.06	91.56	10.73	6.84
Net Income	-$110.29M	-$96.07M	$3.56B	$337.45M
7 Day Performance	N/A	0.29%	1.34%	2.48%
1 Month Performance	43.28%	-0.15%	2.25%	4.36%
1 Year Performance	-57.87%	57.86%	26.20%	32.45%

LianBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIAN LianBio	N/A	$0.16 +44.6%	N/A	-57.9%	$17.28M	N/A	N/A	110	Gap Up
FLNA Cassava Sciences	1.7346 of 5 stars	$1.32 -7.0%	$5.00 +278.8%	-39.0%	$68.60M	N/A	N/A	20
CTOR Citius Oncology	1.9841 of 5 stars	$0.69 -4.6%	$6.00 +773.6%	-54.8%	$66.93M	N/A	N/A	N/A	Positive News High Trading Volume
EXOZ eXoZymes	0.6124 of 5 stars	$7.72 -1.0%	N/A	-44.6%	$66.14M	$70K	N/A	29	High Trading Volume
TCRX TScan Therapeutics	3.3881 of 5 stars	$0.92 -4.9%	$6.00 +553.2%	-41.2%	$63.10M	$10.32M	N/A	100	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIAN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LianBio (LIAN) Competitors

LIAN vs. FLNA, CTOR, EXOZ, TCRX, and CING

How does LianBio compare to Cassava Sciences?

Summary

How does LianBio compare to Citius Oncology?

Summary

How does LianBio compare to eXoZymes?

Summary

How does LianBio compare to TScan Therapeutics?

Summary

How does LianBio compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LianBio (LIAN) Competitors

LIAN vs. FLNA, CTOR, EXOZ, TCRX, and CING

How does LianBio compare to Cassava Sciences?

Do insiders & institutionals hold more shares of FLNA or LIAN?

Do analysts rate FLNA or LIAN?

Which has more risk & volatility, FLNA or LIAN?

Is FLNA or LIAN more profitable?

Which has higher earnings & valuation, FLNA or LIAN?

Does the media refer more to FLNA or LIAN?

Summary

How does LianBio compare to Citius Oncology?

Which has better earnings and valuation, CTOR or LIAN?

Do insiders and institutionals have more ownership in CTOR or LIAN?

Is CTOR or LIAN more profitable?

Which has more risk & volatility, CTOR or LIAN?

Do analysts recommend CTOR or LIAN?

Does the media prefer CTOR or LIAN?

Summary

How does LianBio compare to eXoZymes?

Which has more volatility & risk, EXOZ or LIAN?

Do analysts recommend EXOZ or LIAN?

Do institutionals & insiders hold more shares of EXOZ or LIAN?

Which has preferable earnings & valuation, EXOZ or LIAN?

Is EXOZ or LIAN more profitable?

Does the media refer more to EXOZ or LIAN?

Summary

How does LianBio compare to TScan Therapeutics?

Is LIAN or TCRX more profitable?

Do insiders & institutionals hold more shares of LIAN or TCRX?

Does the media prefer LIAN or TCRX?

Do analysts rate LIAN or TCRX?

Which has stronger earnings and valuation, LIAN or TCRX?

Which has more volatility and risk, LIAN or TCRX?

Summary

How does LianBio compare to Cingulate?

Is CING or LIAN more profitable?

Do analysts prefer CING or LIAN?

Do institutionals and insiders believe in CING or LIAN?

Which has more volatility and risk, CING or LIAN?

Does the media refer more to CING or LIAN?

Which has higher earnings and valuation, CING or LIAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN vs. The Competition

LianBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools